Clinical Trials Logo

Neuromuscular Blockade, Residual clinical trials

View clinical trials related to Neuromuscular Blockade, Residual.

Filter by:
  • None
  • Page 1

NCT ID: NCT06228092 Recruiting - Clinical trials for Neuromuscular Blockade, Residual

Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients

Start date: December 4, 2023
Phase: Phase 4
Study type: Interventional

The aim of this study is to determine the time to TOF ≥ 0.9 after either neostigmine/glycopyrrolate 50 mikrogr/kg or sugammadex 2 mg/kg in patients with age ≥ 75 years. The hypothesis of this study is that sugammadex 2 mg/kg provides a faster time to TOF ≥ 0.9 compared to neostigmine/glycopyrrolate 50 mikrogr/kg.

NCT ID: NCT06193213 Not yet recruiting - Clinical trials for Neuromuscular Blockade, Residual

Incidence of Postoperative Residual Curarization

PORC
Start date: January 2024
Phase:
Study type: Observational

An incomplete postoperative recovery of neuromuscular function (postoperative residual curarization - PORC) represents a common problem in post-anesthesia care units (PACU), potentially exposing the patient to adverse respiratory events. Quantitative and objective evaluation of neuromuscular function using the train acceleromyographic method -of-four ratio (TOFR) at the level of the adductor muscle of the thumb represents the best way to minimize this risk after administration of non-depolarizing neuromuscular agents. Study endpoints Primary endpoint - incidence of postoperative residual curarization Secondary endopoints - number of possible respiratory adverse events during the stay in the PACU and during the hospital stay - estimation of a logistic regression model to define the risk factors associated with residual curarization

NCT ID: NCT06062290 Recruiting - Clinical trials for Postoperative Complications

Does Electromyography Improve Precision and Reliability of Neuromuscular Monitoring in Paediatric Patients

ETCETERA
Start date: September 20, 2023
Phase:
Study type: Observational

Neuromuscular monitoring is used as a standard surveillance method of neuromuscular function to ensure full recovery at the end of anaesthesia. The currently available devices properly provide respective information in adults but not in children. Furthermore, response to neuromuscular blocking agents differs between adults and children due to age-related differences in body composition, physiological function, and acetylcholine receptor density. Recently, electromyographic (EMG) technologies to monitor neuromuscular function were increasingly developed including disposables for nerve stimulation and measurement of the compound muscle action potential in children. However, it is still unclear whether the precision and reliability of these devices is superior to the currently available neuromuscular monitoring for children based on kinemyography (KMG). The ETCETERA study will test the hypothesis that neither EMG nor KMG provides inferior train-of-four readings to the respective reference method in infants and children below five years.

NCT ID: NCT05037006 Not yet recruiting - Clinical trials for Neuromuscular Blockade

Three Different Doses of Neostigmine on the Reversal of Cisatracurium-induced Moderate Neuromuscular Blockade

Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

The aim of the present study will be to evaluate by means of a prospective randomized clinical trial, the time required for the reversal of moderate neuromuscular blockade (NMB) (Train-of-four count = 3; TOFc 3) to Train-of-four ratio (TOFr) > 0.9 and TOFr = 1.0 after administration of different doses of neostigmine (30, 50 and 70 mcg/kg) in patients undergoing general anesthesia with propofol or sevoflurane. In addition, the probability of NMB reversal in less than 10 minutes or 15 minutes after neostigmine administration will be registered.

NCT ID: NCT04512313 Completed - Anesthesia Clinical Trials

A Comparison of Rocuronium 0.3 mg/kg, and 0.9 mg/kg for Induction of Anesthesia in Elderly Patients.

Start date: December 17, 2020
Phase: N/A
Study type: Interventional

The number of elderly patients above 80 years is increasing and a large proportion of these patients will require surgery and anesthesia. During anesthesia neuromuscular blocking agents (NMBA) are administered to facilitate intubating conditions and reduce the trauma to the larynx and vocal cords. There is a risk of residual neuromuscular block when using NMBAs like rocuronium. The aim of this study is to determine the onset time, duration of action and effect on intubating conditions after rocuronium 0.3 mg/kg and 0.9 mg/kg in patients with age ≥ 80 years.